Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder

Completed · Phase 4

Conditions studied: Schizophrenia, Schizoaffective Disorder

In brief

This study will assess whether olanzapine and/or risperidone affect the way the human body uses sugar in the blood.

Key facts

Study ID

NCT00190749

Run by

Eli Lilly and Company

People needed

130

Starts

2003-10-01

Expected to finish

2008-06-01

Last updated by the study team

2010-05-04

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18-65 years old
• Diagnosed with Schizophrenia or Schizoaffective disorder
• Ability to visit the doctor's office for scheduled visits

You may not qualify if…

• Women who are pregnant or breastfeeding
• Have a body mass index (BMI) greater than 40
• Have diabetes, heart disease or any other unstable illness
• Have known positive human immunodeficiency virus (HIV)
• Are currently taking olanzapine, risperidone, clozapine, glucocorticoids, injectable antipsychotics

Where it is running

• For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.